Association Between Bowel Urgency and Intestinal Ultrasound Parameters in Ulcerative Colitis: Insights Into Transmural Inflammation and Symptom Pathophysiology Authors: Kanade Serizawa, Shintaro Sagami, Satoko Umeda, Kunio Asonuma, Moeko Komatsu, Shunsuke Shibui, Masa Maeda, Akira Nogami, Ryo Karashima, Masaru Nakano, Ichiro Maeda, Toshifumi Hibi, Chika Kusano, Taku Kobayashi Published: 2026 ABSTRACT ABSTRACTBackgroundBowel urgency (BU) is a key symptom of ulcerative colitis (UC), often impairing the quality of life. This study aimed to identify intestinal ultrasound parameters associated with BU, given that UC may also have transmural involvement, and compare these with endoscopic activity and biomarkers.MethodsIn this single‐centre prospective study, UC patients undergoing colonoscopy between January 31 and September 27, 2023 were enrolled. Transabdominal and transperineal ultrasound were performed to evaluate bowel wall thickness (BWT), including individual layers (mucosa, submucosa, and muscularis propria), and colour Doppler signal (CDS) in the sigmoid colon and rectum. BU was defined according to the Simple Clinical Colitis Activity Index urgency subscore.ResultsOf 59 patients, 33 (56%) reported BU. Compared with those without BU, patients with BU had significantly higher C‐reactive protein, Mayo Endoscopic Subscore (MES), BWT (descending colon, sigmoid colon, rectum), CDS (sigmoid colon, rectum), and submucosal and muscularis propria thickness in the sigmoid colon (all p < 0.05). Mucosal thickness and faecal calprotectin were not significantly different (p = 0.11 and p = 0.48, respectively). In MES‐adjusted logistic regression, submucosal (p < 0.01) and muscularis propria (p = 0.03) thickness remained associated with BU, whereas mucosal thickness did not (p = 0.97). Receiver operating characteristic analysis showed that sigmoid submucosal thickness had greater diagnostic accuracy than mucosal thickness (AUC 0.77 vs. 0.62, p < 0.05).ConclusionsSigmoid submucosal thickening was associated with BU and suggests that transmural inflammation may contribute to symptom pathophysiology.Trial RegistrationUMIN000050099 Introduction Ulcerative colitis (UC) is a chronic inflammatory disease characterised by symptoms such as bloody diarrhoea, abdominal pain, and increased bowel frequency [1]. Among these, bowel urgency (BU) is a particularly distressing symptom, affecting nearly half of patients, many of whom prioritise its improvement above other symptoms [2, 3, 4]. Despite its prevalence and impact, the mechanisms underlying BU remain unclear. Although BU is associated with endoscopic disease severity, some patients report BU despite absent or minimal endoscopic activity [3], suggesting that superficial inflammation alone does not fully explain this symptom [5, 6]. This highlights the need to look beyond endoscopy to better understand BU pathophysiology. Emerging evidence suggests that inflammation in UC may extend beyond the mucosa to deeper bowel wall layers, including the submucosa and muscularis propria, and that submucosal thickening has been reported as a hallmark of UC‐related inflammation [7, 8, 9]. In addition, decreased rectal compliance, a potential consequence of deeper bowel wall involvement, has been implicated in BU pathophysiology [10, 11, 12]. These findings support the evaluation of the full bowel wall to better understand BU; however, studies examining its relationship with individual colonic segments remain limited. We therefore aimed to evaluate the association between BU and each colonic segment, with particular focus on whether deeper bowel wall alterations, including changes in the submucosal and muscularis propria layers, were associated with BU. Intestinal ultrasound (IUS) is well suited to this purpose because it enables layer‐specific assessment of bowel wall thickness. Therefore, we investigated the association between IUS parameters and BU in patients with UC. Methods Study Design and Patient Population We conducted a single‐centre prospective cross‐sectional study at a tertiary referral centre. Consecutive patients with confirmed diagnosis of UC who underwent colonoscopy between January and September 2023 were eligible during prespecified periods when intestinal ultrasound (IUS) was available. Patients were excluded if they had undergone total colectomy, had infectious gastroenteritis within the previous month or had treatment modification between IUS and colonoscopy. Clinical Indices and Patient‐Reported Outcomes On the day of IUS, patients completed the Simple Clinical Colitis Activity Index (SCCAI) and the numeric rating scale (UNRS; 0 = no urgency to 10 = worst possible urgency) [10, 11, 13]. The partial Mayo score (stool frequency, rectal bleeding, and physician global assessment) was also assessed [14]. Bowel urgency (BU) was defined a priori as any urgency on the SCCAI urgency subscore (none vs. any urgency). Clinical and Laboratory Assessments C‐reactive protein (CRP) and leucine‐rich α2‐glycoprotein (LRG) were measured in blood, and faecal calprotectin (FC) was assessed in stool. When blood or stool samples were not obtained on the day of IUS, we used results from the next visit within 14 weeks provided that no treatment changes occurred in the interim. Detailed methods are described in Supporting Information S1. Intestinal Ultrasound, Endoscopy, and Histology IUS was performed within 1 week of colonoscopy by experienced examiners blinded to endoscopic findings and bowel urgency (BU) status. Ultrasound examinations were performed using the Aplio 500/Aplio Platinum series ultrasound system (Canon Medical Systems Corporation, Tokyo, Japan). For colonic assessment, a convex probe (PVT‐375BT; 1.9–6.0 MHz), a microconvex probe (PVT‐674BT; 4.0–9.0 MHz), and a high‐frequency linear probe (PLT‐704SBT; 3.0–11.0 MHz) were used. For rectal evaluation, transperineal ultrasound (TPUS) was performed using high‐frequency microconvex probes (PVT‐674BT and PVT‐712BT; 4.0–9.0 MHz). Colonic ultrasound was performed in the supine position, whereas TPUS was performed in the left lateral decubitus position. Colonic segments were scanned systematically in transverse and longitudinal planes in real time, and rectal measurements used for the statistical analyses were obtained by TPUS. The rectosigmoid junction was used as the primary landmark to distinguish the rectum from the sigmoid colon; when it was not clearly visualised, the segment overlying the urinary bladder was defined as the rectum and the immediately proximal segment as the sigmoid colon. IUS assessments included bowel wall thickness (BWT), colour Doppler signal (CDS), bowel wall stratification, and the Milan Ultrasound Criteria (MUC). Colonoscopic activity was graded using the Mayo Endoscopic Subscore (MES) for each segment, and endoscopic remission was defined as MES ≤ 1 [15]. Endoscopically, the rectum was defined as the distal 15 cm from the anal verge and the sigmoid colon as the segment from ≥ 15 cm up to the rectosigmoid junction. The endoscopist assigning MES was blinded to ultrasound findings. Rectal biopsies were scored using the simplified Geboes score by board‐certified pathologists blinded to clinical, endoscopic, and ultrasound information. For inter‐rater agreement, stored IUS images were independently reviewed more than 6 months after the index examinations by two blinded reviewers: a sonographer with more than 5 years of IUS experience and an IBUS‐certified gastroenterologist with more than 17 years of experience. Ultrasound settings, detailed measurement procedures, and pathology specimen handling are provided in Supporting Information S1. Outcome The primary aim was to evaluate the association between BU and IUS parameters. Sample Size Calculation The primary aim was to evaluate associations between BU and disease severity as assessed by endoscopy and IUS in UC patients. Based on prior data, BU prevalence was estimated at 50% [4], with a target sample size of 60 set to allow adequate evaluation of two severity indicators (endoscopy and IUS), according to the common rule of 15 events per variable. Statistical Analysis Continuous variables are presented as mean ± SD or median (interquartile range), and categorical variables as proportions. Groups with versus without BU were compared using the Wilcoxon rank‐sum test. Missing FC values were imputed using multiple imputation with 20 imputed datasets. Four variables (BWT, CDS, pMayo score and CRP) were included in the imputation model and were also included in the regression models [16]. Associations between BU severity (SCCAI urgency subscore) and clinical indices, biomarkers, endoscopic activity, and IUS measures were assessed using Spearman correlation. Associations with BU (binary) were evaluated using logistic regression; for each parameter of interest, models were adjusted for MES in the most severely affected segment. Receiver operating characteristic (ROC) curve analysis was used to evaluate the ability of sigmoid bowel wall layer thickness to predict BU, and areas under the curve were compared using the DeLong test. Analyses across bowel segments, wall layers, and biomarkers were exploratory, without correction for multiple comparisons. Statistical analyses were performed using JMP Pro 17.0.0 and R Commander 2.9–1. Further details of the statistical analysis are shown in Supporting Information S1. Ethical Considerations This study was conducted in compliance with ethical standards with approval from the Ethics Committee of Kitasato University Kitasato Institute Hospital (Approval Number: 22038). This study was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (Registration No. UMIN000050099) before patient enrolment commenced. All participants provided written informed consent. Results Patient Characteristics We obtained informed consent from 62 patients; however, two withdrew their consent due to feeling unwell after the colonoscopy. A total of 60 patients were included in this study. One patient was excluded due to treatment changes between colonoscopy and IUS (Supporting Information S1: Figure 1). 53 patients underwent IUS and colonoscopy on the same day. Among the 59 patients, 10 (17.0%) had proctitis, 14 (23.7%) had left‐sided colitis, and 35 (59.3%) had extensive colitis. The median pMayo was 2 [1–3], with 35 patients (59.3%) having MES of 0 or 1. 26 patients (44.1%) did not have BU (SCCAI urgency subscore of 0), while 33 patients (55.9%) reported BU with a subscore of 1 or higher (Table 1). TABLE 1Patient characteristics.Total (n = 59)Supporting Information S1: Figure 1Age, years45 [35–56]Sex, male35 (59.3)Disease duration, years10 [4–20]Disease extentE1 (proctitis)10 (16.9)E2 (left‐sided)14 (23.7)E3 (extensive)35 (59.3)Partial mayo score2 [1–3]Laboratory testsCRP, mg/L0.40 [0.20–1.4]LRG, μg/mL12.3 [10.0–15.9]FC, μg/g273 [55–715.5] a Mayo endoscopic subscore027 (45.8)18 (13.6)212 (20.3)312 (20.3)Simplified geboes score≥ 3.125 (42.4)SCCAI urgency subscore026 (44.1)125 (42.4)26 (10.2)32 (3.4)Prior treatmentsCorticosteroids40 (67.8)Immunomodulator19 (32.2)Advanced therapy20 (33.9) Note: Data are presented as n (%), median [interquartile range].Abbreviations: CRP, C‐reactive protein; FC, faecal calprotectin; LRG, leucine‐rich alpha‐2 glycoprotein; SCCAI, simple clinical colitis activity index. a 15 patients had missing data on faecal calprotectin. Patient characteristics. Note: Data are presented as n (%), median [interquartile range]. Abbreviations: CRP, C‐reactive protein; FC, faecal calprotectin; LRG, leucine‐rich alpha‐2 glycoprotein; SCCAI, simple clinical colitis activity index. 15 patients had missing data on faecal calprotectin. There was a discrepancy between the UNRS and the SCCAI urgency subscore (Supporting Information S1: Figure 2). Among the 26 patients with an SCCAI urgency subscore of 0, five (19%) had a UNRS > 1 (Supporting Information S1: Figure 3). As the UNRS is known to be better suited to intra‐patient comparisons [11], the SCCAI urgency subscore was used for subsequent analyses. Comparison Between Groups With and Without Bowel Urgency Patients with BU had significantly higher CRP (0.5 [0.3–0.7] vs. 0.4 [0.1–0.7], p = 0.04), LRG (14 [11.2–17.7] vs. 10.9 [9–13.9], p < 0.01), pMayo (3 [1–4.5] vs. 1 [0–2], p < 0.01), and MES (2 [0–3] vs. 0 [0–1], p < 0.01), than patients without BU. No significant differences were observed in disease duration (9 [4–19.5] vs. 10.5 [6–22], p = 0.16) or FC levels (280.8 [66–944.6] vs. 166.5 [49–712.9], p = 0.48). In the group with BU, the BWT and CDS of the sigmoid colon and rectum were significantly higher (sigmoid colon BWT: 2.5 [1.5–3.7] vs. 1.5 [1.3–1.9], p < 0.01; sigmoid colon positive CDS (grade 1–3): 10 (30.3%) versus 1 (3.8%), p < 0.01; rectum BWT: 6.2 [5.0–7.4] versus 4.9 [3.6–6.2], p < 0.01; rectum positive CDS: 20 (60.6%) versus 9 (34.6%), p = 0.05), while no significant association was observed between BU and BWT in the ascending colon (1.7 [1.1–2.4] vs. 1.4 [1.0–1.7], p = 0.13) or transverse colon (2.3 [1.3–3.1] vs. 2.2 [1.4–2.7], p = 0.61). There was no significant difference in the MUC (3.9 [3.2–7.1] vs. 3.5 [3.1–5.0], p = 0.18). Histological inflammation (sGS ≧ 3.1) was significantly associated with BU (18 (54.5%) versus 6 (23.1%), p = 0.03) (Table 2). TABLE 2Patient characteristics were divided into two groups based on the presence or absence of urgency.Urgency absentUrgency present p value(n = 26)(n = 33)Age, years43.5 [35–52.5]48 [34.5–57.5]0.56Sex, male15 (57.7)20 (60.6)Disease duration, years10.5 [6–22]9 [4–19.5]0.16Disease extent0.45Proctitis6 (23.1)4 (12.1)0.18Left‐sided6 (23.1)8 (24.2)0.24Extensive14 (53.8)21 (63.6)0.3Laboratory testsCRP, mg/L0.4 [0.1–0.7]0.5 [0.3–0.7]0.04LRG, μg/mL10.9 [9–13.9]14 [11.2–17.7]< 0.01FC, μg/g166.5 [49–712.9]280.8 [66–944.6]0.48Partial Mayo score1 [0–2]3 [1–4.5]< 0.01Mayo endoscopic subscore0 [0–1]2 [0–3]< 0.01Simplified Geboes score≧ 3.16180.03Bowel wall thickness, mmAscending colon1.4 [1.0–1.7]1.7 [1.1–2.4]0.13Transverse colon2.2 [1.4–2.7]2.3 [1.3–3.1]0.61Descending colon1.6 [1.3–2.5]2.5 [1.8–3.3]< 0.01Sigmoid colon1.5 [1.3–1.9]2.5 [1.5–3.7]< 0.01Rectum4.9 [3.6–6.2]6.2 [5.0–7.4]< 0.01Colour Doppler signal (1–3), n Ascending colon2 (7.7)3 (9.1)0.88Transverse colon4 (15.4)5 (15.2)0.98Descending colon2 (7.7)8 (24.2)0.08Sigmoid colon1 (3.8)10 (30.3)< 0.01Rectum9 (34.6)20 (60.6)0.05Bowel wall stratification (uncertain, or loss), n Ascending colon020.12Transverse colon220.77Descending colon230.84Sigmoid colon040.03Rectum a 590.47Layer‐specific bowel wall thickness of sigmoid colon, mmM0.4 [0.30–0.58]0.5 [0.40–0.90]0.11SM0.5 [0.40–0.60]0.9 [0.50–1.42]< 0.01MP0.6 [0.43–0.78]1.0 [0.60–1.20]< 0.01MUC3.5 [3.1–5.0]3.9 [3.2–7.1]0.18 Note: Data are presented as n (%), median [interquartile range].Abbreviations: CRP, C‐reactive protein; FC, faecal calprotectin; LRG, leucine‐rich alpha‐2 glycoprotein; M, mucosa; MP, Muscularis propria; MUC, Milan ultrasound criteria; SM, submucosa. a Rectal ultrasound values were obtained from transperineal ultrasound. Patient characteristics were divided into two groups based on the presence or absence of urgency. Note: Data are presented as n (%), median [interquartile range]. Abbreviations: CRP, C‐reactive protein; FC, faecal calprotectin; LRG, leucine‐rich alpha‐2 glycoprotein; M, mucosa; MP, Muscularis propria; MUC, Milan ultrasound criteria; SM, submucosa. Rectal ultrasound values were obtained from transperineal ultrasound. Relationship Between Clinical, Endoscopic, and IUS Parameters and Bowel Urgency Spearman's rank correlation analysis revealed moderate correlations between BU and BWT in the rectum (r s = 0.44, p < 0.01) and sigmoid colon (r s = 0.45, p < 0.01), while correlations with CDS in these segments were significant but slightly weaker (rectum CDS: r s = 0.38, p < 0.01; sigmoid colon CDS: r s = 0.35, p < 0.01). The correlation with MUC was also weak (r s = 0.21, p = 0.12) (Figure 1). Correlations between the SCCAI urgency subscore and segmental endoscopic activity (segmental MES) as well as biomarkers (CRP, LRG, and FC) are provided in Supporting Information S1: Figures 4 and 5. In addition, to confirm anatomical alignment at the segmental level, we examined the concordance between disease severity assessed by IUS and by colonoscopy in the sigmoid colon and rectum, which showed significant correlations (data not shown). Correlation between SCCAI urgency subscore and (A) BWT, (B) CDS on TPUS in the rectum, (C) BWT, (D) CDS in the sigmoid colon, and (E) MUC. BWT, bowel wall thickness; CDS, colour Doppler signal; MUC, Milan ultrasound criteria; TPUS, transperineal ultrasound. Moderate correlations were found between BU and thickness of both submucosal (r s = 0.55, p < 0.01) and muscularis propria (r s = 0.41, p < 0.01) layers, while the correlation with mucosal thickness was weak (r s = 0.24, p = 0.07) when the sigmoid colon was analysed by individual layers (Figure 2A–C). In contrast, the rectal wall layer revealed weaker correlations with BU: mucosa (r s = 0.32, p = 0.02), submucosa (r s = 0.24, p = 0.08), and muscularis propria (r s = 0.34, p = 0.01) (Figure 2D–F). Correlation between layer‐specific bowel wall thickness and SCCAI urgency subscore in the sigmoid colon (A–C) and rectum (D–F). Univariate logistic regression showed that IUS parameters, especially bowel wall layer thickness in the sigmoid colon, were strongly associated with BU. Sigmoid submucosal thickness (OR 46.63, 95% CI 3.88–560.21) and muscularis propria thickness (OR 23.23, 95% CI 3.03–177.82) demonstrated the strongest associations, whereas mucosal thickness did not. After adjusting for endoscopic severity, both submucosal (OR 33.43, 95% CI 2.04–548.37) and muscularis propria thickness (OR 11.05, 95% CI 1.19–102.96) in the sigmoid colon remained significant. Exploratory penalised regression and bootstrap resampling analyses yielded broadly consistent directions of association for the key sigmoid layer‐specific findings (Supporting Information S1: Table 1,2). In contrast, CRP and LRG were associated with BU in univariate analysis but lost significance after adjustment (Table 3). The findings remained unchanged in a sensitivity analysis defining remission as MES = 0 (data not shown). The findings remained directionally consistent in a sensitivity analysis excluding proctitis (E1), with sigmoid submucosal and muscularis propria thickness remaining associated with bowel urgency. Additional adjustment for disease extent (E2 vs. E3) in the E1‐excluded cohort did not materially change these results (Supporting Information S1: Table 3,4). TABLE 3Logistic regression analysis for factors associated with urgency.Crude odds ratioAdjusted odds ratio e Odds ratio95% CI p valueOdds ratio95% CI p valueBiomarkersCRP, mg/L a 1.740.91–3.300.091.580.79–3.170.20LRG, μg/mL a 1.191.03–1.370.021.120.95–1.320.19FC, μg/g b 1.020.98–1.070.271.000.99–1.000.61Endoscopic activity (MES ≥ 2)Most severe segment8.472.37–30.24< 0.01Sigmoid colon— d ——Rectum303.63–248.18< 0.01Intestinal ultrasoundMUC a 1.670.52–5.340.390.910.64–1.300.59Sigmoid colonTotal BWT c 3.681.60–8.47< 0.012.751.07–7.040.04M c 4.380.80–23.910.091.040.13–8.280.97SM c 46.633.88–560.21< 0.0133.432.04–548.37< 0.01MP c 23.233.03–177.82< 0.0111.051.19–102.960.03CDS a 9.231.15–74.080.044.040.46–35.800.21Rectum f Total BWT f 1.751.19–2.57< 0.011.480.98–2.230.06M c 3.261.27–10.40.031.870.58–6.780.31SM c 1.390.82–2.40.231.030.55–1.940.91MP c 1.940.96–4.40.071.710.74–4.370.21CDS a 2.571.16–5.680.021.70.75–3.900.21HistologysGS ≥ 3.13.261.08–9.830.041.170.29–4.650.82 Note: Logistic regression analysis examining the association of urgency, as indicated by SCCAI urgency subscore, with symptoms, biomarkers, endoscopic activity, several parameters of intestinal ultrasound, and histological activity.Abbreviations: BWT, bowel wall thickness; CDS, colour Doppler signal; CI, confidence interval; CRP, C‐reactive protein; FC, faecal calprotectin; LRG, leucine‐rich alpha‐2 glycoprotein; M, mucosa; MES, Mayo endoscopic subscore; MP, Muscularis propria; MUC, Milan ultrasound criteria; sGS, simplified Geboes score; SM, submucosa. a The odds ratio associated with a one‐unit increase. b The odds ratio associated with a 100‐unit increase. c The odds ratio associated with a one‐mm increase. d All patients with bowel urgency had active endoscopic findings. e Adjusted for MES at the most severe segment. f All ultrasound values were measured by transperineal ultrasound. Logistic regression analysis for factors associated with urgency. Note: Logistic regression analysis examining the association of urgency, as indicated by SCCAI urgency subscore, with symptoms, biomarkers, endoscopic activity, several parameters of intestinal ultrasound, and histological activity. Abbreviations: BWT, bowel wall thickness; CDS, colour Doppler signal; CI, confidence interval; CRP, C‐reactive protein; FC, faecal calprotectin; LRG, leucine‐rich alpha‐2 glycoprotein; M, mucosa; MES, Mayo endoscopic subscore; MP, Muscularis propria; MUC, Milan ultrasound criteria; sGS, simplified Geboes score; SM, submucosa. The odds ratio associated with a one‐unit increase. The odds ratio associated with a 100‐unit increase. The odds ratio associated with a one‐mm increase. All patients with bowel urgency had active endoscopic findings. Adjusted for MES at the most severe segment. All ultrasound values were measured by transperineal ultrasound. In the rectum, none of the individual wall layers remained significantly associated with BU after adjustment (mucosa: OR 1.87, 95% CI 0.58–6.78, p = 0.31; submucosa: OR 1.03, 95% CI 0.55–1.94, p = 0.91; muscularis propria: OR 1.71, 95% CI 0.74–4.37, p = 0.21). A supplementary analysis using UNRS and SCCAI subscores as a continuous endpoints yielded broadly similar associations (Supporting Information S1: Table 5, 6). Given its strong association with BU, ROC analysis was performed for sigmoid submucosal thickness. The AUC for the submucosa (AUC 0.77, 95% CI 0.59–0.84) and muscularis propria (AUC 0.74, 95% CI 0.57–0.77) of the sigmoid colon were predictive. The predictability of the submucosal thickness was significantly better than that of the mucosa (Estimate −0.15, p < 0.05) (Figure 3). Receiver operating characteristic (ROC) analysis of the thickness of each sigmoid colon layer for urgency. AUC, area under the curve; CI, confidence interval; M, mucosa (mm); MP, muscularis propria (mm); SM, submucosa (mm). Inter‐Observer Agreement for Sigmoid Submucosal Thickness Measurement The inter‐observer agreement for submucosal thickness measurements in the sigmoid colon was high with a kappa coefficient of 0.69. Kappa was calculated after dichotomising continuous sigmoid submucosal thickness at 0.75 mm (cut‐off determined by the Youden Index) to define positive versus negative findings for each rater. Discussion To our knowledge, this is the first study to examine associations between BU and layer‐specific IUS parameters in UC, providing insight into the mechanisms underlying this debilitating symptom. Our findings indicate that sigmoid BWT is significantly associated with BU. Importantly, submucosal and muscularis propria thickening emerged as key contributors, whereas the mucosal layer was not significantly associated with BU. The association between BU and deeper bowel wall changes suggests that deeper bowel wall involvement may contribute to symptom pathophysiology in UC. The submucosal Meissner's plexus and the Auerbach's plexus in the muscularis propria may mediate this relationship [17, 18]. Submucosal inflammation may impair physiological mucus secretion, while disruption of the muscularis propria may alter peristalsis, both contributing to BU. These findings are consistent with reports identifying submucosal thickening as a sensitive marker of disease severity in UC [8] and highlight the clinical relevance of transmural pathology. The association persisted after adjustment for endoscopic severity in this cohort. Thus, although endoscopy remains central to UC assessment, it may not fully capture the deeper bowel wall changes underlying symptoms such as BU. This has important clinical implications, supporting a complementary role for IUS in assessing deeper bowel wall involvement, particularly in patients with persistent symptoms despite minimal endoscopic activity. CRP and LRG were more strongly associated with BU than FC, possibly because FC mainly reflects mucosal inflammation, whereas LRG may better capture broader and potentially deeper bowel wall inflammation, consistent with previous reports showing correlations between LRG and IUS parameters in Crohn's disease [19, 20]. FC may also be influenced by more proximal inflammation, which could weaken its relationship with segmental MES and BU. Most samples were obtained within 14 days, and sensitivity analyses showed similar trends. The relatively mild BWT and MUC values in the bowel urgency cohort should be interpreted with caution as these indices reflect inflammatory activity rather than symptom burden. In our cohort, bowel urgency appeared to relate more specifically to sigmoid layer‐specific abnormalities than to overall composite ultrasound activity. The composite nature of MUC may therefore explain both its mild values and its lack of a significant association with bowel urgency. The rectum is the most directly implicated segment in BU. Classical physiological studies have shown that active UC is associated with reduced rectal compliance, heightened rectal sensitivity, and lower urge thresholds, all of which correlate strongly with BU [11, 12]. The sigmoid colon may also contribute to BU through mechanisms distinct from those operating in the rectum. Clinical improvement of BU with topical therapies that reach both the rectum and sigmoid colon suggests that inflammation in this segment is clinically relevant [21, 22]. In addition, dysfunction at the rectosigmoid junction may permit premature or unregulated stool entry into the rectum, thereby triggering urgency [23, 24, 25, 26, 27]. Supporting this concept, previous ultrasound studies have reported sigmoid wall thickening in patients with irritable bowel syndrome, a condition in which BU is also a prominent symptom [28]. Collectively, these findings indicate that both the rectum and sigmoid colon contribute to BU through distinct but complementary mechanisms. The sensitivity analysis excluding proctitis, together with the additional adjustment for disease extent, suggested that the sigmoid findings were not solely driven by rectal‐limited disease. In the present cohort, rectal TPUS measurements showed weaker associations with BU than with sigmoid findings. This may reflect the technical challenges of layer‐specific rectal assessment by TPUS as well as the complex pathophysiology of urgency involving not only the rectum but also the rectosigmoid region. Thus, the limited apparent value of rectal TPUS in this study does not exclude the role of the rectum in BU. IUS may therefore help identify clinically relevant deeper bowel wall changes in symptomatic patients. The prospective design and blinded IUS assessments strengthen the internal validity of our findings, although whether submucosal and muscularis propria thickening improves with treatment remains uncertain and requires further study. Several limitations merit consideration. First, the sample size was modest, and the small number of patients with inflammation confined solely to the sigmoid colon limited subgroup evaluation of this phenotype. Second, layer‐specific BWT measurement is technically demanding, although inter‐rater reliability for sigmoid submucosal thickness was good; however, this agreement was based on dichotomised rather than full continuous measurements. In addition, because 53 of 59 patients underwent IUS on the same day after colonoscopy, some measurement bias cannot be excluded; however, this influence is limited for the sigmoid colon, where intraluminal contents are usually minimal and anatomical fixation allows stable probe compression. Third, although the UNRS is considered more suitable for assessing within‐patient change over time, we used the SCCAI urgency subscore to define BU because it is better suited to between‐patient categorisation. In addition, BU may at times reflect prior experiences of faecal incontinence rather than current urgency [29]. Fourth, analyses involving multiple bowel segments, wall layers, and biomarkers were exploratory and no formal correction for multiple comparisons was applied, given the small dataset and the potential for residual functional and psychological confounding. Consequently, individual p values should be interpreted cautiously, and the findings require external validation. In conclusion, our findings indicate that BU is associated with thickening of the submucosal and muscularis propria layers, rather than the mucosal layer, as assessed by IUS. These results offer novel insights into the pathophysiology of BU, suggesting that transmural or deeper bowel wall changes may contribute to symptom pathophysiology in UC and highlighting the value of IUS in assessing these changes. Author Contributions K.S. was involved in patient recruitment, study conception, data curation/formal analysis, manuscript drafting, and contributed to its review and editing. S. Sagami contributed to patient recruitment, methodology support, data curation, supervision of data curation/analysis, manuscript drafting, and review/editing. S.U., M.K., S. Shibui, M.M., A.N., and R.K. contributed to patient recruitment and manuscript review/editing. K.A., I.M., M.N., and T.H. contributed to data curation and manuscript review/editing. C.K. reviewed and edited the manuscript. T.K. contributed to patient recruitment, study conception, supervision of data curation/analysis, manuscript drafting, and review/editing. All authors have approved the final version of the manuscript. Conflicts of Interest Shintaro Sagami has received speaker fees from AbbVie, Eli Lilly, Janssen Pharmaceutical K.K., Gilead Sciences Inc., JIMRO Co. Ltd., KISSEI Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, EA Pharma Co. Ltd., Takeda Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., and Zeria Pharmaceutical Co. Ltd.; held endowed chairs funded by AbbVie, JIMRO Co. Ltd., Zeria Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co. Ltd., and EA Pharma Co. Ltd.; and received research grants from Pfizer Inc., Bristol‐Myers Squibb, and Ferring Pharmaceuticals. Akira Nogami has received speaker fees from AbbVie GK. Kunio Asonuma has received speaker fees from Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., EA Pharma Co. Ltd., Pfizer Japan Inc., and Mochida Pharmaceutical Co. Ltd. Masaru Nakano has received speaker or consultancy fees from Covidien, Mochida Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., and Nippon Kayaku Co. Ltd.; and research funding from Mitsubishi Tanabe Pharma Corporation and the Japanese Foundation for Research and Promotion of Endoscopy. Toshifumi Hibi has received lecture fees from AbbVie GK, JIMRO Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co. Ltd., Sandoz K.K., Takeda Pharmaceutical Co. Ltd., and Zeria Pharmaceutical Co. Ltd.; consultancy fees from AbbVie GK, Celltrion, Eli Lilly, Gilead Sciences, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd., and Zeria Pharmaceutical Co. Ltd.; and research grants from AbbVie GK, Activaid, Alfresa Pharma Corporation, JMDC Inc., Gilead Sciences Inc., Nippon Kayaku Co. Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Ferring Pharmaceuticals, and Bristol‐Myers Squibb. He has also received sponsorship from Alfresa Pharma Corporation, JIMRO Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co. Ltd., Miyarisan Pharmaceutical Co. Ltd., and Zeria Pharmaceutical Co. Ltd. Chika Kusano has received lecture fees from AbbVie GK, Takeda Pharmaceutical Co. Ltd., and EA Pharma Co. Ltd. Taku Kobayashi has received lecture fees from AbbVie GK, Activaid, EA Pharma Co. Ltd., Janssen Pharmaceutical K.K., Gilead Sciences Inc., JIMRO Co. Ltd., KISSEI Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Miyarisan Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and Zeria Pharmaceutical Co. Ltd.; research grants from AbbVie GK, Activaid, Alfresa Pharma Corporation, Bristol‐Myers Squibb, Eli Lilly, Ferring Pharmaceuticals Japan K.K., Gilead Sciences Inc., JMDC Inc., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd.; and scholarship contributions from Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co. Ltd., and Zeria Pharmaceutical Co. Ltd. He is also affiliated with study groups supported by Alfresa Pharma Corporation, JIMRO Co. Ltd., Kyorin Pharmaceutical Co. Ltd., Mochida Pharmaceutical Co. Ltd., and Zeria Pharmaceutical Co. Ltd. He has received consultancy fees from AbbVie GK, Activaid, Celltrion Healthcare, EA Pharma Co. Ltd., Eli Lilly, Ferring Pharmaceuticals Japan K.K., Gilead Sciences, Janssen Pharmaceutical K.K., KISSEI Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd. The authors not listed have no conflicts of interest to declare. Supporting information Supporting Information S1